Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

The Role of BCR-ABL Levels Fluctuations and Loss of Deep Molecular Response after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia in the Prospective Trial RU-SKI

Anna Petrova, MD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anastasiya Bykova, MD, Irina Nemchenko, MD PhD, Olga Pospelova, MD, Margarita Gurianova, MD, Nikolay Tsyba, MD PhD, Tatiana I. Ionova, Prof., Anna G. Turkina, Prof., MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141798

Published: 2020

Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Blood (2019) 134 (Supplement_1): 1638.

https://doi.org/10.1182/blood-2019-127951

Published: 2019

Journal Articles

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Tatyana Ionova, PhD Professor, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Petrova, MD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G. Turkina, Prof., MD

Blood (2019) 134 (Supplement_1): 2925.

https://doi.org/10.1182/blood-2019-122041

Published: 2019

Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Blood (2018) 132 (Supplement 1): 790.

https://doi.org/10.1182/blood-2018-99-116803

Published: 2018

Journal Articles

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Anna Petrova, MD, Ekaterina Chelysheva, MD PhD, Oleg Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G Turkina, Prof., MD, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Zinkovskaya, Tatiana Ionova, DSc

Blood (2018) 132 (Supplement 1): 3023.

https://doi.org/10.1182/blood-2018-99-113360

Published: 2018

Journal Articles

Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

Oleg Shukhov, MD PhD, Ekaterina Chelysheva, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Irina Nemchenko, MD PhD, Galina Gusarova, MD PhD, Eduard Gemdzhian, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2018-99-116321

Published: 2018

Journal Articles

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Anna G Turkina, Prof., MD, Oleg Shukhov, MDPhD, Ekaterina Chelysheva, MDPhD, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD

Blood (2017) 130 (Supplement 1): 895.

https://doi.org/10.1182/blood.V130.Suppl_1.895.895

Published: 2017

NARROW

The Role of BCR-ABL Levels Fluctuations and Loss of Deep Molecular Response after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia in the Prospective Trial RU-SKI

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Email alerts

ASH Publications

American Society of Hematology

The Role of BCR-ABL Levels Fluctuations and Loss of Deep Molecular Response after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia in the Prospective Trial RU-SKI

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only